AXGN vs SYK: fair value comparison
Axogen, Inc. and Stryker Corporation · Updated 2026-10-19
AXGN is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, SYK currently ranks higher by quality score.
| AXGN | SYK | |
|---|---|---|
| Verdict | Awaiting full valuation | Undervalued |
| Last price | $34.62 | $277.33 |
| 12-month range | $17.77–$51.73 | $269.75–$387.46 |
| Rank by discount to fair value | — | #12 of 108 Healthcare |
| Rank by quality score | #34 of 301 Healthcare | #32 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: AXGN fair value analysis · SYK fair value analysis